- Lipocine Announces Positive LPCN 2401 Clinical Results Showing Improved Body Composition in Participants with Obesity
- Lipocine Announces Positive Week 52 Results from LPCN 1148 Phase 2 Study in Patients with Cirrhosis
- Lipocine Announces First Cohort Dosed in Pivotal Study of LPCN 1154
- Lipocine Announces Financial Results for the Full Year Ended December 31, 2023
- Lipocine to Present at 36th Annual Roth Conference
- Lipocine Announces Confirmation of Dosing Regimen for Pivotal Study of LPCN 1154
- Lipocine Announces Continued Commercialization of TLANDO® through Verity Pharmaceuticals
More ▼
Key statistics
On Friday, Lipocine Inc (LPCN:NAQ) closed at 4.80, -32.90% below its 52-week high of 7.15, set on Apr 11, 2024.
52-week range
Short selling activityProvided by S&P Global Market Intelligence
Open | 4.52 |
---|---|
High | 4.81 |
Low | 4.51 |
Bid | 4.50 |
Offer | 4.80 |
Previous close | 4.55 |
Average volume | 39.29k |
---|---|
Shares outstanding | 5.32m |
Free float | 5.16m |
P/E (TTM) | -- |
Market cap | 25.50m USD |
EPS (TTM) | -3.11 USD |
Data delayed at least 15 minutes, as of Apr 26 2024 20:49 BST.
More ▼